A key highlight will be Brenntag’s qualified amino acids portfolio
The company will soon be launching a new portfolio of products in this segment
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The formulation is backed by over 80 clinical trials and 200 scientific publications
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
Subscribe To Our Newsletter & Stay Updated